These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 31112476)

  • 1. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
    Ramchandren R; Domingo-Domènech E; Rueda A; Trněný M; Feldman TA; Lee HJ; Provencio M; Sillaber C; Cohen JB; Savage KJ; Willenbacher W; Ligon AH; Ouyang J; Redd R; Rodig SJ; Shipp MA; Sacchi M; Sumbul A; Armand P; Ansell SM
    J Clin Oncol; 2019 Aug; 37(23):1997-2007. PubMed ID: 31112476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
    Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
    JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Shipp MA; Kato K; Sumbul A; Farsaci B; Ansell SM
    J Clin Oncol; 2018 May; 36(14):1428-1439. PubMed ID: 29584546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
    Herrera AF; LeBlanc M; Castellino SM; Li H; Rutherford SC; Evens AM; Davison K; Punnett A; Parsons SK; Ahmed S; Casulo C; Bartlett NL; Tuscano JM; Mei MG; Hess BT; Jacobs R; Saeed H; Torka P; Hu B; Moskowitz C; Kaur S; Goyal G; Forlenza C; Doan A; Lamble A; Kumar P; Chowdhury S; Brinker B; Sharma N; Singh A; Blum KA; Perry AM; Kovach A; Hodgson D; Constine LS; Shields LK; Prica A; Dillon H; Little RF; Shipp MA; Crump M; Kahl B; Leonard JP; Smith SM; Song JY; Kelly KM; Friedberg JW
    N Engl J Med; 2024 Oct; 391(15):1379-1389. PubMed ID: 39413375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
    Allen PB; Savas H; Evens AM; Advani RH; Palmer B; Pro B; Karmali R; Mou E; Bearden J; Dillehay G; Bayer RA; Eisner RM; Chmiel JS; O'Shea K; Gordon LI; Winter JN
    Blood; 2021 Mar; 137(10):1318-1326. PubMed ID: 32992341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
    Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
    J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
    Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
    JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    Kumar A; Casulo C; Advani RH; Budde E; Barr PM; Batlevi CL; Caron P; Constine LS; Dandapani SV; Drill E; Drullinsky P; Friedberg JW; Grieve C; Hamilton A; Hamlin PA; Hoppe RT; Horwitz SM; Joseph A; Khan N; Laraque L; Matasar MJ; Moskowitz AJ; Noy A; Palomba ML; Schöder H; Straus DJ; Vemuri S; Yang J; Younes A; Zelenetz AD; Yahalom J; Moskowitz CH
    J Clin Oncol; 2021 Jul; 39(20):2257-2265. PubMed ID: 33909449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
    Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ
    J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
    De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A
    J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
    Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
    J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP; Rodig SJ; Martín-Regueira P; Sumbul A; Samakoglu S; Tang H; Ansell SM
    Blood; 2021 Feb; 137(5):637-645. PubMed ID: 32870269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Management of older patients with Hodgkin lymphoma: implications of S1826.
    McKenna M; Ryu Tiger YK; Rutherford SC; Evens AM
    Semin Hematol; 2024 Aug; 61(4):236-244. PubMed ID: 38945791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Beköz H; Karadurmuş N; Paydaş S; Türker A; Toptaş T; Fıratlı Tuğlular T; Sönmez M; Gülbaş Z; Tekgündüz E; Kaya AH; Özbalak M; Taştemir N; Kaynar L; Yıldırım R; Karadoğan I; Arat M; Pepedil Tanrıkulu F; Özkocaman V; Abalı H; Turgut M; Kurt Yüksel M; Özcan M; Doğu MH; Kabukçu Hacıoğlu S; Barışta I; Demirkaya M; Köseoğlu FD; Toprak SK; Yılmaz M; Demirkürek HC; Demirkol O; Ferhanoğlu B
    Ann Oncol; 2017 Oct; 28(10):2496-2502. PubMed ID: 28961828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.